Intimation of loss of share certificate / issue of duplicate share certificate under regulation
39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the
Listing Regulations")
Dear Sir / Madam,
Pursuant to Regulation 39(3) of the Listing Regulations, we have received information of loss of share certificate and request for issue of duplicate share certificate as under:
Sr.
Folio
Name
of
the
Certificate
Distinctive Numbers
No.
of
No.
Number
shareholder
No.
From
To
shares
1.
049642
DILIP HIRJI SHAH
1673
1846246
1846995
750
Please bring the above information to the notice of investors at large.
Thanking you,
Yours faithfully,
For, ZYDUS LIFESCIENCES LIMITED
DHAVAL NARENDRA SONI
Digitally signed by
DHAVAL NARENDRA SONI Date: 2022.08.24 14:00:31 +05'30'
DHAVAL N. SONI COMPANY SECRETARY
Attachments
Original Link
Original Document
Permalink
Disclaimer
Zydus Lifesciences Ltd. published this content on 24 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 August 2022 10:17:08 UTC.
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.